Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Replimune's ebitda for the twelve months ending Sep 30, 2026 was -$266.43M. For fiscal 2026 it was -$316.59M. The highest annual figure on record is -$9.53M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$316.59M | – |
| FY2025 | Mar 31, 2025 | -$258.13M | – |
| FY2024 | Mar 31, 2024 | -$232.12M | – |
| FY2023 | Mar 31, 2023 | -$174.63M | – |
| FY2022 | Mar 31, 2022 | -$116.17M | – |
| FY2021 | Mar 31, 2021 | -$78.24M | – |
| FY2020 | Mar 31, 2020 | -$55.67M | – |
| FY2019 | Mar 31, 2019 | -$30.80M | – |
| FY2018 | Mar 31, 2018 | -$19.12M | – |
| FY2017 | Mar 31, 2017 | -$9.53M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$55.48M | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$67.31M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$72.57M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$71.07M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$83.49M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$89.55M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$78.48M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$65.02M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$58.02M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$56.63M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$58.05M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$55.84M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$63.13M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$55.03M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$52.47M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$40.95M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$40.96M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$40.26M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$31.44M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$29.15M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$28.72M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$26.86M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$21.69M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$19.87M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$19.24M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$17.44M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$16.04M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$16.56M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$12.20M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$10.87M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$7.78M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$10.10M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$7.07M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$5.85M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$7.04M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$4.70M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$4.23M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$3.15M | – |
See a number that looks wrong?